# A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00664898** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** SGN-40

## Key facts

- **NCT ID:** NCT00664898
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-04-08
- **Final completion:** 2010-04-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00664898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00664898, "A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00664898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*